Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25472499 | 0.85 | CYP1A2 (0.33) | CYP2C19CYP1A2MAPK1SLC22A1 | |
| SCHEMBL3972281 | 0.81 | CYP2C19 (0.43) | CYP2C19MEN1KMT2AGLACYP1A2 | |
| SCHEMBL250410 | 0.81 | CYP2C19 (0.43) | CYP2C19MEN1KMT2AGLACYP1A2 | |
| SCHEMBL19501664 | 0.80 | PRMT3 (0.44) | CYP1A2MAPK1SLC22A1 | |
| SCHEMBL6141818 | 0.79 | CYP2C9 (0.39) | CYP2C19CYP1A2MAPK1 | |
| SCHEMBL9079152 | 0.79 | CYP2C19 (0.41) | CYP2C19MEN1KMT2AGLACYP1A2 | |
| Hydrochloric Acid SCHEMBL29183274 | 0.79 | CYP2C19 (0.41) | CYP2C19MEN1KMT2AGLACYP1A2 | |
| Ammonia Solution, Strong SCHEMBL11798888 | 0.79 | CYP2C19 (0.41) | CYP2C19MEN1KMT2AGLACYP1A2 | |
| SCHEMBL8803099 | 0.79 | CYP2C19 (0.41) | CYP2C19MEN1KMT2AGLACYP1A2 | |
| SCHEMBL9323979 | 0.78 | PLA2G1B (0.36) | CYP2C19MEN1KMT2AGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | ASCENDIS PHARMA AS (DK) | 2012-03-08 | — | — | US | disclosed |
| EP-2403537-A1 | INTERFERON ALPHA CARRIER PRODRUGS | Ascendis Pharma A/S (DK) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010100220-A1 | INTERFERON ALPHA CARRIER PRODRUGS | ASCENDIS PHARMA AS (DK) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | IFNG, IFNAR1, IRF3 | CYP2C19 98/4885MEN1 4083/4885KMT2A 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.